FDA Adverse Events Reports (FAERS) Summary for TRIAMCINOLONE ACETONIDE

These tables and charts are based on 23,526 total reports for TRIAMCINOLONE ACETONIDE (TRIAMCINOLONE ACETONIDE) received by the FDA Adverse Event Reporting System (FAERS) from 2004 through April 28, 2026.

This FAERS total includes 22,904 pharmaceutical company-submitted and non-U.S. FAERS reports and 622 U.S. consumer or healthcare provider-submitted MedWatch reports. For a separate summary of the 622 U.S. reports filed via the FDA MedWatch voluntary reporting system, view our FDA MedWatch TRIAMCINOLONE ACETONIDE summary report. (See notes section below for explanation of FDA’s mandatory and voluntary reporting system.)

Top 20 Adverse Effects Associated with TRIAMCINOLONE ACETONIDE (reported in FAERS Database)

	Side Effect	# of FDA Reports
1	DRUG INEFFECTIVE	3700
2	OFF LABEL USE	2681
3	ITCHING	2352
4	RASH	2332
5	PAIN	2024
6	FATIGUE	1931
7	NAUSEA	1835
8	PRODUCT USE IN UNAPPROVED INDICATION	1624
9	CONDITION AGGRAVATED	1619
10	DIARRHEA	1605
11	VOMITING	1592
12	HEADACHE	1504
13	JOINT PAIN	1402
14	DIZZINESS	1326
15	FEVER	1302
16	MALAISE	1296
17	INFUSION RELATED REACTION	1287
18	JOINT INFLAMMATION	1269
19	RHEUMATOID ARTHRITIS	1249
20	HIVES	1248
21	WEIGHT INCREASED	1241
22	JOINT SWELLING	1202
23	NUMBNESS	1196
24	HIGH BLOOD PRESSURE	1181
25	SHORTNESS OF BREATH	1164
26	LUPUS	1148
27	SWELLING	1143
28	WOUND	1138
29	HYPERSENSITIVITY	1077
30	BURNING MOUTH SYNDROME	1076
31	LOWER LIMBS SWELLING	1073
32	PSORIATIC ARTHRITIS	1059
33	MOBILITY DECREASED	1049
34	HAND DEFORMITY	1048
35	COMMON COLD	1048
36	TYPE 2 DIABETES MELLITUS	1040
37	HAIR LOSS	1035
38	DRUG INTOLERANCE	1022
39	IMPAIRED HEALING	1022
40	PAIN IN EXTREMITY	1016
41	WHEEZING	1014
42	INFLAMMATION OF HAIR FOLLICLES	1009
43	INFECTION	1001
44	STOMATITIS	989
45	FIBROMYALGIA	972
46	ABDOMINAL DISCOMFORT	967
47	INSOMNIA	965
48	IRRITABLE BOWEL SYNDROME	960
49	PSORIASIS	958
50	BLISTERS	957
51	GENERAL PHYSICAL HEALTH DETERIORATION	947
52	PNEUMONIA	945
53	DRUG HYPERSENSITIVITY	937
54	SLEEP DISORDER	929
55	ELEVATED LIVER ENZYMES	919
56	JOINT PAIN	906
57	HELICOBACTER INFECTION	906
58	CONFUSIONAL STATE	900
59	DRY SKIN	898
60	LACK OF STRENGTH AND ENERGY (ASTHENIA)	895
61	DUODENAL ULCER PERFORATION	890
62	JOINT RANGE OF MOTION DECREASED	879
63	INTENTIONAL PRODUCT USE ISSUE	874
64	INJURY	866
65	PERICARDITIS	859
66	WEIGHT DECREASED	849
67	INFLAMMATION	847
68	PRODUCT USE ISSUE	846
69	BLISTER	837
70	DRY MOUTH	817
71	ABDOMINAL PAIN UPPER	803
72	OBESITY	800
73	SINUSITIS	797
74	ILL-DEFINED DISORDER	791
75	C-REACTIVE PROTEIN INCREASED	785
76	MACULAR DEGENERATION	780
77	DEPRESSION	776
78	ECZEMA	771
79	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE	762
80	OSTEOARTHRITIS	748
81	DRUG EFFECT INCOMPLETE	746
82	RHEUMATIC FEVER	743
83	TREATMENT FAILURE	734
84	MEMORY IMPAIRMENT	730
85	PINS AND NEEDLES	730
86	INDIGESTION	729
87	DECREASED APPETITE	728
88	BLOOD CHOLESTEROL INCREASED	721
89	MUSCLE INJURY	718
90	MUSCLE SPASMS	714
91	ABDOMINAL PAIN	713
92	THERAPEUTIC PRODUCT EFFECT DECREASED	711
93	SKIN PEELING	707
94	LIVER INJURY	700
95	MATERNAL EXPOSURE DURING PREGNANCY	699
96	LIP DRY	697
97	FACET JOINT SYNDROME	694
98	LOWER RESPIRATORY TRACT INFECTION	688
99	SKIN REDNESS	687
100	WOUND INFECTION	679

Latest Known Outcomes for Reactions Reported for TRIAMCINOLONE ACETONIDE

	Latest Known Outcome for Reported Reactions	Number of Cases
1	Unknown Outcome	14844
2	Patient has not recovered/symtoms have not resolved	4933
3	Patient recovered	4368
4	Patient died	2737
5	Patient is recovering/symptoms resolving	2354
6	Patient has recovered but has consequent health issues	106

Search all MedWatch and FAERS by keyword:

TRIAMCINOLONE ACETONIDE Total Reports

Male	Female	Unknown	Total
7191	13545	2790	23,526

Top Countries Reporting

	Country	Number of Reports
1	United States	15793
2	Canada	4093
3	Japan	370
4	United Kingdom	247
5	China	230
6	India	226
7	Netherlands	152
8	Germany	148
9	Spain	95
10	Italy	90

Outcomes for Reports

Serious: 12993
Not Serious: 10514
Note: A serious outcome means the adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition.

Top Indications

Product used for unknown indication
Psoriasis
Intervertebral disc protrusion
JOINT PAIN
Multiple sclerosis

Top Companies Reporting

PADAGIS
ENCUBE ETHICALS
BRISTOL MYERS SQUIBB
CHATTEM
SANDOZ
GLENMARK
ALKEM
BRISTOL-MYERS SQUIBB COMPANY
QUAGEN PHARMACEUTICALS

Safety-Related FDA Updates

FDA Approval Date: 1987-10-16

KENALOG-10 (TRIAMCINOLONE ACETONIDE) Rx Drug:
Risk of infection with various pathogens, including viral, bacterial, fungal, protozoan, or helminthic (parasitic) Safety-related Labeling Changes

Have experience (good or bad) with KENALOG-10? Rate KENALOG-10 at Ask a Patient.

KENALOG-40 (TRIAMCINOLONE ACETONIDE) Rx Drug:
Safety-related Labeling Changes

Have experience (good or bad) with KENALOG-40? Rate KENALOG-40 at Ask a Patient.

ZILRETTA (TRIAMCINOLONE ACETONIDE) Rx Drug:
Safety-related Labeling Changes

Have experience (good or bad) with ZILRETTA? Rate ZILRETTA at Ask a Patient.

For serious adverse events, report them to the FDA by contacting the drug manufacturer or report directly through the MedWatch voluntary reporting form.

Notes

This report, created by AskaPatient.com, is derived from the cases for TRIAMCINOLONE ACETONIDE reported to the United States Food and Drug Administration (FDA) FDA Safety Information and Adverse Event Reporting System (FAERS) and obtained from Open FDA. Data was last updated with reports received through April 28, 2026.

This summary includes ALL reports where the drug is a "primary OR secondary OR suspected interacting" drug. Typically, reports are filed for the most serious type or "event" and do not represent incidental or minor side effects. The majority of these reports are mandatory reports submitted by pharmaceutical companies, who receive complaints from consumers. The reactions, side effects, or "adverse events," represent up to the 20 most frequently occuring events in the database for a drug related to the event. This report also features counts of latest known outcomes associated with reported side effects, but does not provide the specific outcomes for specific adverse events.

Adverse Event Reports are submitted to the FAERS database by pharmaceutical companies (mandatory reporting is required by manufacturers, distributors, or importers). Health care providers such as doctors (voluntary reporting), and patients themselves (voluntary reporting) report to the FDA directly through the MedWatch program. Those MedWatch reports are coded and included in the FAERS database. This report mainly consists of the mandatory reports, because the MedWatch reports are a small percentage (3 - 5%) of total reports. Link to the MedWatch summary report at the top of the page for a summary of the directly reported (voluntary) adverse events for this drug.The number of reports included here might differ somewhat from the number of reports in the downloadable quarterly FAERS reports and in the online FAERS dashboard, due to lags in reporting, drug name differences, duplicates, and other factors. Open FDA states that it only includes the most recent version of a case report. It also adds the disclaimer: "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated."

FDA uses the "MedDRA" classification system to describe reported adverse reactions. MedDRA is a standardized medical terminology that facilitates sharing of regulatory information internationally. In some cases, "patient friendly" terms for the layman designated by MedDRA have been substituted for medical jargon. Please contact us with questions or comments about this report.